Study to assess the rollout of a genetic-guided prescribing service in UK General Practice
- Conditions
- Assessment of pharmacogenetic guided prescribing across a range of commonly prescribed medicine classes, initiated in primary care.Not Applicable
- Registration Number
- ISRCTN15390784
- Lead Sponsor
- Manchester University NHS Foundation Trust
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Ongoing
- Sex
- All
- Target Recruitment
- 1450
1. Participants must be a registered patient at one of the recruiting GP practices.
2. Participants must have capacity to independently consent.
3. Participants must be 18 years of age or over.
4. Participants must be being considered for a new prescription of one of four medicines classes, or participants being considered for an agent change within one of the four medicine classes. The eligible medicine classes (and specific medicines) are:
4.1. Selective Serotonin Reuptake Inhibitors [citalopram, escitalopram, fluvoxamine, paroxetine, sertraline]
4.2. Tricyclic Antidepressants (prescribed for pain or depression) [amitriptyline, clomipramine, doxepin, imipramine, nortriptyline, trimipramine]
4.3. Statin Therapy [atorvastatin, fluvastatin, pravastatin, rosuvastatin, simvastatin]
4.4. Proton Pump Inhibitors [esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole]
1. Patients unable to independently consent.
2. Patients under the age of 18 years.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The Pharmacogenetic Clinical Utility Metric (Defined as the proportion of patients across the study cohort with a CPIC Level 1A variant related to the medicine which triggered recruitment to the study) – determined through genetic testing as part of study
- Secondary Outcome Measures
Name Time Method